Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook

Moderna Inc. (MRNA) shares tumbled Monday after the company revised its 2025 revenue forecast, causing a decline in the stock price. The biotechnology company now expects its 2025 sales to fall between $1.5 billion and $2.5 billion, a significant decrease from its previous guidance of $2.5 billion to $3.5 billion. This revision comes as the company faces increased competition in the COVID market, falling vaccination rates, and uncertainty around manufacturing contracts and RSV revaccination recommendations.

Moderna's stock price has been on a downward trend for some time, and the recent revision in revenue guidance has exacerbated this decline. The company's shares fell by 19% in morning trading, reaching a new 52-week low. This decline has raised concerns among investors about the company's future prospects and its ability to maintain its cash position.



As Moderna's stock price continues to decline, investors are closely watching several key price levels. The first support level of interest is around $30, which is near the prominent April 2019 swing high and closely aligns with several price points during the COVID-era volatility in early March 2020. If the bulls fail to defend this level, the stock could retest the $13 level, where bargain hunters could look to scoop up shares near the stock's pronounced December 2018 and August 2019 swing lows.

On the resistance side, investors should initially keep an eye on the $57 level. The shares could run into overhead resistance at this price point near a trendline that links the June and September 2020 lows with a period of brief consolidation that formed on the chart in late October last year. Buying above this level could see a move up to around $68, a level where investors who have purchased shares at lower prices could seek exit points near the October 2020 pullback low and November 2023 trough.

Moderna's revised revenue guidance and the subsequent decline in its stock price have raised questions about the company's ability to maintain its cash position and invest in new products. The company has announced plans to cut cash costs by $1 billion in 2025 and an additional $500 million in 2026, which could help preserve its cash and ensure its long-term financial health. However, investors will be closely watching the company's performance and its ability to execute on its cost-cutting initiatives in the coming months.

In conclusion, Moderna's revised revenue guidance and the subsequent decline in its stock price have raised concerns among investors about the company's future prospects. As the stock continues to decline, investors are closely watching several key price levels, including support around $30 and resistance near $57 and $68. The company's ability to maintain its cash position and invest in new products will be crucial in determining its long-term success.